RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR NEUROTROPHIC KERATITIS - P&T Community https://t.co/iMcpST9hH3
— IDRO (@IDROOhio) December 5, 2018
from Twitter https://twitter.com/IDROOhio
December 05, 2018 at 08:36AM
No comments:
Post a Comment